Calypso Biotech

Calypso Biotech is the third spin-off company from the EPP Fund. The company is developing antibody therapeutics against niche gastro-intestinal immune disorders, such as refractory celiac disease and Crohn`s Disease. Calypso Biotech is based in Geneva, Switzerland.

Team Member
more about
Jasper Bos
Latest News Entry
Calypso Biotech licenses CALY-001 best-in-class anti-MMP-9 antibody to EA Pharma

Calypso Biotech SA announced today that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd. to develop CALY-001, a best-in-class anti-MMP-9 fully human monoclonal antibody.

all portfolio news